Expert Ratings For Innovid
Portfolio Pulse from Benzinga Insights
Innovid (NYSE:CTV) has received mixed analyst ratings over the past three months, with recent updates showing a positive shift in sentiment. The average 12-month price target for Innovid is now $2.39, marking a 34.27% increase from the previous target of $1.78. Analysts from Needham and Morgan Stanley have raised their price targets, reflecting optimism about the company's performance. Innovid's financials show a positive revenue trend with a 14.6% growth rate and strong profitability indicators, despite a market capitalization below industry averages.
May 08, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Innovid has seen a positive shift in analyst sentiment, with an increased average price target of $2.39. Financial performance indicators are strong, with significant revenue growth and profitability metrics above industry averages.
The positive shift in analyst ratings and the increase in the average price target suggest growing confidence in Innovid's financial health and market position. The company's strong revenue growth and profitability metrics further support this optimism, likely leading to a positive short-term impact on its stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100